Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19

Ruqaiyyah Siddiqui; Naveed Ahmed Khan

doi:10.1021/acschemneuro.0c00288

Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19

ACS Chem Neurosci. 2020 Jun 3;11(11):1523-1524. doi: 10.1021/acschemneuro.0c00288. Epub 2020 May 20.

Authors

Ruqaiyyah Siddiqui¹, Naveed Ahmed Khan¹

Affiliation

¹ Department of Biology, Chemistry and Environmental Sciences, College of Arts and Sciences, American University of Sharjah, University City, Sharjah, United Arab Emirates.

PMID: 32432466
DOI: 10.1021/acschemneuro.0c00288

Abstract

There is mounting evidence of the central nervous system manifestations associated with COVID-19, particularly in severe cases. Up to 25% of COVID-19 cases exhibit neurological manifestations associated with COVID-19. In view of the devastating nature of the disease due to severe acute respiratory syndrome coronavirus 2, here we debate intranasal drug delivery, in addition to intravenous delivery, as a therapeutic strategy in the management of COVID-19 cases with central nervous system involvement.

Keywords: COVID-19; central nervous system; intranasal; neurological manifestation; severe acute respiratory syndrome coronavirus 2.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Intranasal / methods*
Administration, Intravenous
COVID-19
Central Nervous System Viral Diseases / drug therapy*
Coronavirus Infections / drug therapy*
Humans
Pandemics
Pneumonia, Viral / drug therapy*